The latest price target for Agios Pharmaceuticals (NASDAQ:AGIO) was reported by RBC Capital on November 1, 2024. The analyst firm set a price target for $55.00 expecting AGIO to fall to within 12 months (a possible -1.13% downside). 17 analyst firms have reported ratings in the last year.

The latest analyst rating for Agios Pharmaceuticals (NASDAQ:AGIO) was provided by RBC Capital, and Agios Pharmaceuticals reiterated their outperform rating.

The last upgrade for Agios Pharmaceuticals Inc happened on November 17, 2022 when Goldman Sachs raised their price target to $32. Goldman Sachs previously had a sell for Agios Pharmaceuticals Inc.

The last downgrade for Agios Pharmaceuticals Inc happened on September 27, 2024 when Leerink Partners changed their price target from $60 to $56 for Agios Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Agios Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Agios Pharmaceuticals was filed on November 1, 2024 so you should expect the next rating to be made available sometime around November 1, 2025.

While ratings are subjective and will change, the latest Agios Pharmaceuticals (AGIO) rating was a reiterated with a price target of $55.00 to $55.00. The current price Agios Pharmaceuticals (AGIO) is trading at is $55.63, which is out of the analyst’s predicted range.